Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

OTC Markets EXMKT - Delayed Quote USD

MedinCell S.A. (MDCLF)

Compare

6.98

0.00

(0.00%)

At close: March 3 at 3:00:00 PM EST

3 European Growth Companies With Up To 19% Insider Ownership

As European markets navigate a landscape marked by cautious optimism amid U.S. trade policy developments and geopolitical efforts, investors are increasingly focused on companies with strong growth potential. In this environment, stocks with high insider ownership can be particularly appealing, as they often indicate confidence in the company's future prospects from those closest to its operations.

Simply Wall St. 5 days ago

MDCLF
0.00%
RTOBF

LCTSF
Medincell to Present at the TD Cowen 45th Annual Healthcare Conference, March 3-5, 2025, Boston, MA

MONTPELLIER, France, February 26, 2025--Regulatory News: Medincell (Paris:MEDCL):

Business Wire 5 days ago

MDCLF
0.00%
Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS, February 25, 2025--Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the supplemental New Drug Application (sNDA) for UZEDY extended-release injectable suspension for the maintenance treatment of BP-I in adults has been accepted for filing by the U.S. Food and Drug Administration (FDA).

Business Wire 6 days ago

TEVA

TEVJF

MDCLF
0.00%
Medincell Announces Successful c.€43 Million Global Offering

MONTPELLIER, France, February 19, 2025--Regulatory News: Medincell (Paris:MEDCL):

Business Wire 13 days ago

MDCLF
0.00%
Medincell Launches a Global Offering for Approximately 10% of Its Share Capital

MONTPELLIER, France, February 18, 2025--Regulatory News: Medincell (Paris:MEDCL):

Business Wire 13 days ago

MDCLF
0.00%
Medincell: Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

MONTPELLIER, France, February 10, 2025--Regulatory News: Medincell (Paris:MEDCL):

Business Wire 22 days ago

MDCLF
0.00%
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

MONTPELLIER, France, February 10, 2025--Medincell (Paris:MEDCL): ACCESS HERE THE FULL PRESS RELEASE

Business Wire 22 days ago

MDCLF
0.00%
The EIB Reaffirms Confidence in Medincell by Permanently Waiving Two Financial Covenants in its Loan Agreement

MONTPELLIER, France, February 06, 2025--Regulatory News: Medincell (Paris:MEDCL):

Business Wire 25 days ago

MDCLF
0.00%
Medincell: UZEDY® Surges to $117M in Sales in 2024, First Full Year of Commercialization

MONTPELLIER, France, January 29, 2025--Regulatory News: Medincell’s (Paris:MEDCL) partner Teva Pharmaceuticals shared today the following information:

Business Wire last month

MDCLF
0.00%
3 Growth Companies With High Insider Ownership To Watch

As global markets continue their upward trajectory, driven by optimism surrounding AI advancements and a potential easing of trade tensions, growth stocks have notably outperformed value shares for the first time this year. In such an environment, companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the business best.

Simply Wall St. last month

MDCLF
0.00%
LFTSF

SWDCF
Medincell: Publication of the 2025 Financial Calendar

MONTPELLIER, France, January 15, 2025--Regulatory News: Medincell (Paris:MEDCL):

Business Wire last month

MDCLF
0.00%
Top Growth Companies With Strong Insider Ownership December 2024

As global markets navigate a landscape marked by rate cuts from the ECB and SNB, alongside expectations for a Federal Reserve cut, growth stocks have continued to outperform their value counterparts, with the Nasdaq Composite reaching new heights. Amidst this backdrop of economic shifts and market volatility, companies with strong insider ownership can offer unique insights into potential growth trajectories, as insiders often align their interests closely with shareholders.

Simply Wall St. 2 months ago

AKESF

MDCLF
0.00%
Medincell to Join the Euronext SBF 120 Index

MONTPELLIER, France, December 12, 2024--Regulatory News: Medincell (Paris:MEDCL) joins the Euronext SBF 120 index, which includes the 120 largest companies listed on Euronext Paris, including the CAC 40 and most of the key players in the French economy. Medincell joins also the CAC Mid 60 index.

Business Wire 2 months ago

MDCLF
0.00%
Medincell Publishes Its Consolidated Half-year Financial Results

MONTPELLIER, France, December 10, 2024--Regulatory News: Medincell (Paris:MEDCL):

Business Wire 2 months ago

MDCLF
0.00%
Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM: Major Subgroup Analysis Shows Reduced Pain and Opioid Use, and Accelerated Rehabilitation following Total Knee Replacement

MONTPELLIER, France, December 09, 2024--Analysis of a major subgroup of patients undergoing a first Total Knee Replacement (TKR), representing over 70% of the trial population (108 out of 151), revealed the following benefits when comparing patients treated with F14/mdc-CWM (n=51) to those in the control group (n=57)1:

Business Wire 2 months ago

MDCLF
0.00%
Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 10th, 2024

MONTPELLIER, France, November 28, 2024--Regulatory News: Medincell (Paris:MEDCL) will hold a videoconference on Tuesday December 10th, 2024 to present the half-year financial results (April 2024-September 2024)

Business Wire 3 months ago

MDCLF
0.00%
MedinCell And 2 Other Top Growth Stocks With Strong Insider Ownership

In the midst of a volatile global market landscape, characterized by fluctuating sector performances and shifting economic policies, investors are seeking stability and potential growth opportunities. One strategy gaining attention is focusing on growth companies with high insider ownership, as these stocks often indicate strong confidence from those closest to the company's operations and future prospects.

Simply Wall St. 3 months ago

MDCLF
0.00%
Medincell: 25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI Clinical Phase 3

MONTPELLIER, France, November 06, 2024--ACCESS HERE THE COMPLETE PRESS RELEASE

Business Wire 3 months ago

MDCLF
0.00%
Medincell’s Partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY® at Psych Congress 20241

MONTPELLIER, France, November 04, 2024--Medincell (Paris:MEDCL): ACCESS HERE THE COMPLETE PRESS RELEASE

Business Wire 3 months ago

MDCLF
0.00%
Medincell Announces Participation in Leading Investor Conferences

MONTPELLIER, France, October 28, 2024--Regulatory News: Members of Medincell’s (Paris:MEDCL) management team will participate in the following investor conferences in November and December 2024.

Business Wire 4 months ago

MDCLF
0.00%

Performance Overview

Return	MDCLF	CAC 40
YTD	0.00%	+9.36%
1-Year	0.00%	+1.45%
3-Year	-28.08%	+33.16%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MedinCell S.A. (MDCLF)

3 European Growth Companies With Up To 19% Insider Ownership

Medincell to Present at the TD Cowen 45th Annual Healthcare Conference, March 3-5, 2025, Boston, MA

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

Medincell Announces Successful c.€43 Million Global Offering

Medincell Launches a Global Offering for Approximately 10% of Its Share Capital

Medincell: Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

The EIB Reaffirms Confidence in Medincell by Permanently Waiving Two Financial Covenants in its Loan Agreement

Medincell: UZEDY® Surges to $117M in Sales in 2024, First Full Year of Commercialization

3 Growth Companies With High Insider Ownership To Watch

Medincell: Publication of the 2025 Financial Calendar

Top Growth Companies With Strong Insider Ownership December 2024

Medincell to Join the Euronext SBF 120 Index

Medincell Publishes Its Consolidated Half-year Financial Results

Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM: Major Subgroup Analysis Shows Reduced Pain and Opioid Use, and Accelerated Rehabilitation following Total Knee Replacement

Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 10th, 2024

MedinCell And 2 Other Top Growth Stocks With Strong Insider Ownership

Medincell: 25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI Clinical Phase 3

Medincell’s Partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY® at Psych Congress 20241

Medincell Announces Participation in Leading Investor Conferences

Performance Overview